Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage

References

• Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, et al. 2003. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 63:3755–3763.
   PubMed Web of Science ®Google Scholar
• Bai J, Guo XG, Bai XP. 2012. Epidermal growth factor receptor-related DNA repair and radiation-resistance regulatory mechanisms: a mini-review. Asian Pac J Cancer Prev. 13:4879–4881.
   PubMedGoogle Scholar
• Belli V, Sforza V, Cardone C, Martinelli E, Barra G, Matrone N, Napolitano S, Morgillo F, Tuccillo C, Federico A, et al. 2017. Regorafenib in combination with Silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. Oncotarget. 8:68305–68316.
   PubMedGoogle Scholar
• Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. 2016. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 11:674–690.
   Google Scholar
• Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. 2018. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 17:34–51.
   PubMed Web of Science ®Google Scholar
• Cann KL, Hicks GG. 2007. Regulation of the cellular DNA double-strand break response. Biochem Cell Biol. 85:663–674.
   PubMed Web of Science ®Google Scholar
• Chou RH, Wang YN, Hsieh YH, Li LY, Xia W, Chang WC, Chang LC, Cheng CC, Lai CC, Hsu JL, et al. 2014. EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4. Dev Cell. 30:224–237.
   PubMed Web of Science ®Google Scholar
• Collignon J, Lousberg L, Schroeder H, Jerusalem G. 2016. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press). 8:93–107.
   PubMed Web of Science ®Google Scholar
• Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A. 2007. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene. 26:2423–2434.
   PubMed Web of Science ®Google Scholar
• Crona DJ, Keisler MD, Walko CM. 2013. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. Ann Pharmacother. 47:1685–1696.
   PubMed Web of Science ®Google Scholar
• Daudigeos-Dubus E, Le Dret L, Lanvers-Kaminsky C, Bawa O, Opolon P, Vievard A, Villa I, Pagès M, Bosq J, Vassal G, et al. 2015. Regorafenib: antitumor activity upon mono and combination therapy in preclinical pediatric malignancy models. PLoS One. 10:e0142612.
   PubMed Web of Science ®Google Scholar
• Davis SL, Eckhardt SG, Messersmith WA, Jimeno A. 2013. The development of Regorafenib and its current and potential future role in cancer therapy. Drugs Today. 49:105–115.
   PubMed Web of Science ®Google Scholar
• De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C. 2011. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 103:645–661.
   PubMedGoogle Scholar
• de la Fouchardière C. 2018. Regorafenib in the treatment of metastatic colorectal cancer. Future Oncol. 14:2239–2246.
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. 2003. MAPK pathways in radiation responses. Oncogene. 22:5885–5896.
   PubMed Web of Science ®Google Scholar
• Ettrich TJ, Seufferlein T. 2014. Regorafenib – recent results. Recent Results Cancer Res. 201:185–196.
   PubMedGoogle Scholar
• Goel G. 2018. Evolution of Regorafenib from bench to bedside in colorectal cancer: is it an attractive option or merely a “me too” drug? Cancer Manag Res. 10:425–437.
   PubMed Web of Science ®Google Scholar
• Guryanova OA, Bao S. 2011. How scatter factor receptor c-MET contributes to tumor radioresistance: ready, set, scatter! J Natl Cancer Inst. 103:617–619.
   PubMedGoogle Scholar
• Hu X, Wu LW, Zhang ZY, Chen ML, Li YL, Zhang C. 2018. The anti-tumor effect of Regorafenib in lung squamous cell carcinoma in vitro. Biochem Biophys Res Commun. 503:1123–1129.
   PubMed Web of Science ®Google Scholar
• Karar J, Maity A. 2009. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther. 8:1994–2001.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Chun SY, Nam KS, Kim S. 2015. Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1. Oncol Rep. 34:884–890.
   PubMed Web of Science ®Google Scholar
• Li P, Veldwijk MR, Zhang Q, Li ZB, Xu WC, Fu S. 2013. Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells. BMC Cancer. 13:297–305.
   PubMed Web of Science ®Google Scholar
• Liccardi G, Hartley JA, Hochhauser D. 2011. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 71:1103–1114.
   PubMed Web of Science ®Google Scholar
• Lin CY, Lin TH, Chen CC, Chen MC, Chen CP. 2018. Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: a single center, retrospective study. PLoS One. 13:e0190497.
   PubMed Web of Science ®Google Scholar
• Liu YC, Wu RH, Wang WS. 2017. Regorafenib diminishes the expression and secretion of angiogenesis and metastasis associated proteins and inhibits cell invasion via NF-κB inactivation in SK-Hep1 cells. Oncol Lett. 14:461–467.
   PubMed Web of Science ®Google Scholar
• Mahajan K, Mahajan NP. 2015. Cross talk of tyrosine kinases with the DNA damage signaling pathways. Nucleic Acids Res. 43:10588–10601.
   PubMed Web of Science ®Google Scholar
• Malinda KM, Nomizu M, Chung M, Delgado M, Kuratomi Y, Yamada Y, Kleinman HK, Ponce ML. 1999. Identification of laminin a1 and b1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J. 13:53–62.
   PubMed Web of Science ®Google Scholar
• Mehta M, Basalingappa K, Griffith JN, Andrade D, Babu A, Amreddy N, Muralidharan R, Gorospe M, Herman T, Ding WQ, et al. 2016. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 7:64820–64835.
   PubMed Web of Science ®Google Scholar
• Meyn RE, Munshi A, Haymach J, Milas L, Ang KK. 2009. Receptor signaling as a regulatory mechanism of DNA repair. Radiotherapy and Oncol. 92:316–322.
   PubMed Web of Science ®Google Scholar
• Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. 2006. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther. 5:1967–1974.
   PubMed Web of Science ®Google Scholar
• Muralidharan R, Mehta M, Ahmed R, Roy S, Xu L, Aubé J, Chen A, Zhao YD, Herman T, Ramesh R, et al. 2017. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci Rep. 7:9694.
   PubMed Web of Science ®Google Scholar
• Norbury CJ, Zhivotovsky B. 2004. DNA damage-induced apoptosis. Oncogene. 23:2797–2808.
   PubMed Web of Science ®Google Scholar
• Olive PL, Wlodek D, Banáth JP. 1991. DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. Cancer Res. 51:4671–4676.
   PubMed Web of Science ®Google Scholar
• Panneerselvam J, Jin J, Shanker M, Lauderdale J, Bates J, Wang Q, Zhao YD, Archibald SJ, Hubin TJ, Ramesh R. 2015. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS One. 10:e0122439.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Jr Martino S, Mamounas EP, Kaufman PA, Wolmark N. 2011. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 29:3366–3373.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A. 2016. Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer. Transl Oncol. 9:453–457.
   PubMed Web of Science ®Google Scholar
• Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, et al. 2011. Vandetanib restores head and neck squamous cell carcinoma cells’ sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res. 17:1815–1827.
   PubMed Web of Science ®Google Scholar
• Santivasi WL, Xia F. 2014. Ionizing radiation-induced DNA damage, response, and repair. Antioxid Redox Signal. 21:251–259.
   PubMed Web of Science ®Google Scholar
• Sirohi B, Philip DS, Shrikhande SV. 2014. Regorafenib in gastrointestinal stromal tumors. Future Oncol. 10:1581–1587.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Schultheis B. 2012. Regorafenib for cancer. Expert Opin Investig Drugs. 21:879–889.
   PubMed Web of Science ®Google Scholar
• Su JC, Mar AC, Wu SH, Tai WT, Chu PY, Wu CY, Tseng LM, Lee TC, Chen KF, Liu CY, et al. 2016. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. Sci Rep. 6:28888.
   PubMed Web of Science ®Google Scholar
• Wachsberger P, Burd R, Dicker AP. 2003. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 9:1957–1971.
   PubMed Web of Science ®Google Scholar
• Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. 2008. Inhibition of vascular endothelial growth factor signaling using Cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumor xenografts. Br J Radiol. 81:S21–S27.
   PubMed Web of Science ®Google Scholar